Search

This study investigates the effect of daily consumption of wheat biscuits enriched with plant proteins in postprandial metabolic responses of women with overweight/obesity who follow an energy-restricted diet. Thirty apparently healthy women participated in a 12-week randomized controlled trial and were assigned either to a control (CB) or an intervention (PB) group. Participants consumed daily either a conventional (CB) or an isocaloric wheat biscuit enriched with plant proteins (PB) containing high amounts of amino acids with appetite-regulating properties, i.e., BCAAs and L-arg. At baseline and the end of the intervention, a mixed meal tolerance test was performed. The responses of glucose, insulin, ghrelin, GLP-1, and glicentin were evaluated over 180 min. After 12 weeks, both groups experienced significant decreases in body weight, fat mass, and waist circumference. In the PB group, a trend towards higher weight loss was observed, accompanied by lower carbohydrate, fat, and energy intakes (p < 0.05 compared to baseline and CB group), while decreases in fasting insulin and the HOMA-IR index were also observed (p < 0.05 compared to baseline). In both groups, similar postprandial glucose, ghrelin, and GLP-1 responses were detected, while iAUC for insulin was lower (p < 0.05). Interestingly, the iAUC of glicentin was greater in the PB group (p < 0.05 compared to baseline). Subjective appetite ratings were beneficially affected in both groups (p < 0.05). Consumption of wheat biscuits enriched in plant proteins contributed to greater weight loss, lower energy intake, and insulin resistance and had a positive impact on postprandial glicentin response, a peptide that can potentially predict long-term weight loss and decreased food intake. [ABSTRACT FROM AUTHOR]

L-Arg is a nonessential amino acid but has many physiological roles. Accordingly, L-Arg has been used in various fields, but there is only limited information available about its safety upon overdose. Generally, the no-observed adverse effect level (NOAEL) is used when setting the upper amount for chemical substances. Recently, systematic reviews have been used to assess the safety as well as the effectiveness and usefulness of them. Therefore, we conducted an assessment of the safety of the oral intake of L-Arg in healthy subjects using gastrointestinal symptoms as an index. We limited the study design to only double-blind randomized controlled trials and searched PubMed, Cochrane Library, EBSCOhost, and Ichushi-Web from inception until May 2021. Assessment of the quality of studies was conducted using the Cochrane Collaboration tool and Jadad score, and the random effects model was used for data analysis. Ultimately, 34 studies were selected for inclusion in this work. The dosage of L-Arg used in the studies ranged from 2000 to 30,000 mg/day (or/one-time dose), and the treatment duration was 1–84 days. The increased risk of gastrointestinal symptoms associated with L-Arg intake from 23 studies (647 participants in total) in which such symptoms were reported was 0.01 (95% confidence interval: – 0.02–0.04), which was not significant difference. NOAEL was estimated as 7531 mg/ one-time dose using a weighted change-point regression model (UMIN000046133). Registration and protocol: Umin.ac.jp as UMIN000046133. [ABSTRACT FROM AUTHOR]

L-arginine (L-Arg) is a semi-essential amino acid with many important physiological functions. However, achieving efficient manufacture of L-Arg on an industrial scale using Escherichia coli (E. coli) remains a major challenge. In previous studies, we constructed a strain of E. coli A7, which had good L-Arg production capacity. In this study, E. coli A7 was further modified, and E. coli A21 with more efficient L-Arg production capacity was obtained. Firstly, we reduced the acetate accumulation of strain A7 by weakening the poxB gene and overexpressing acs gene. Secondly, we improved the L-Arg transport efficiency of strains by overexpressing the lysE gene from Corynebacterium glutamicum (C. glutamicum). Finally, we enhanced the supplies of precursors for the synthesis of L-Arg and optimized the supplies of cofactor NADPH and energy ATP in strain. After fermentation in a 5-L bioreactor, the L-Arg titer of strain A21 was found to be 89.7 g/L. The productivity was 1.495 g/(L·h) and the glucose yield was 0.377 g/g. Our study further narrowed the titer gap between E. coli and C. glutamicum in the synthesis of L-Arg. In all recent studies on the L-Arg production by E. coli, this was the highest titer recorded. In conclusion, our study further promotes the efficient mass synthesis of L-Arg by E. coli. Key points: • The acetate accumulation of starting strain A7 was decreased. • Overexpression of gene lysE of C. glutamicum enhanced L-Arg transport in strain A10. • Enhance the supplies of precursors for the synthesis of L-Arg and optimize the supplies of cofactor NADPH and energy ATP. Finally, Strain A21 was detected to have an L-Arg titer of 89.7 g/L in a 5-L bioreactor. [ABSTRACT FROM AUTHOR]

Introduction: Hepatic ischemia reperfusion injury (IRI) takes place through liver transplantation. Hepatic IRI might seriously affect liver function and is reported to be accountable for 15 % of organ failure and could result in multi-organ dysfunction syndrome (MODS) that lead to high rates of morbidity and mortality. L-arginine (L-Arg) could reduce hepatic IRI via different mechanisms Objective: To estimate the effect of hepatic ischemic reperfusion (I/R) and the possible protective effect of L-Arg. on the adrenal cortex. Materials and Methods: Thirty two albino rats were utilized in the current work. The animals split to Sham-Operation, L-Arg, ischemic reperfusion, I/R group and I/R and L-Arg group. Then, at the assigned time, blood samples were assembled for biochemical study. Histological and immunohistochemical studies were performed on the adrenal tissue. Results: The adrenal cortex of I/R group exhibited architecture loss of the three zones. Zona glomerulosa cells showed small pyknotic nuclei and vacuolated cytoplasm. Zona fasciculata cells appeared ballooned with small pyknotic nuclei. Also, karyolitic nuclei were seen. zona reticularis cells showed pyknotic nuclei and vacuolated cytoplasm and separated by congested blood sinusoids. Hyaline material depositions were seen. Biochemical study revealed a marked increase in serum levels of liver enzymes, excess in the MDA level and a marked reduction in the CAT level compared to control group. These changes were ameliorated by L-Arg. Conclusion: Hepatic I/R has been proved to induce histological changes of the adrenal cortex which could be ameliorated by administration of L-Arg. Therefore, For inhibiting or reducing hepatic IRI through liver surgery, an effective method is urgently required. [ABSTRACT FROM AUTHOR]

Copyright of Shipin Kexue/ Food Science is the property of Food Science Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Context: Broiler meat with excessive of fat and saturated fatty acids content has serious health implication for consumers. The accumulation of abdominal fats in broiler chickens constitutes a loss of dietary energy and also reduces carcass yield. Oil rich in unsaturated fatty acids and l-arginine are effective for reducing fat deposition and improve meat quality. Aims: The aim of this study was to examine the effects of supplementation of l-arginine (l-Arg) with four combinations of palm oil (PO) and sunflower oil (SO) on growth performance, carcass yield, fat deposition, lipogenic gene expression and blood lipid profile in broiler chickens. Methods: A total of 180 1-day-old chicks (Cobb 500) were randomly assigned to five dietary treatments as: T1, 6% PO (control); T2, 6% PO + 0.25% l-Arg; T3, 4% PO + 2% SO + 0.25% l-Arg; T4, 2% PO + 4% SO + 0.25% l-Arg; and T5, 6% SO + 0.25% l-Arg. Key results: Birds fed l-Arg and combinations of PO and SO had higher weight gain at starter and finisher period compared with the control. The carcass yield increased, and relative abdominal fat reduced in broiler fed with combinations of l-Arg and increased level of SO in the diet. The concentration of oleic, palmitoleic and total monounsaturated fatty acids in liver tissue decreased by addition of l-Arg in broiler diet. The palmitic and total saturated fatty acid decreased, and total unsaturated fatty acid and polyunsaturated fatty acids increased in liver tissue when PO replaced progressively by SO supplemented with l-Arg in the diet. The acetyl-CoA carboxylase , stearoyl-CoA desaturase and fatty acid synthetase gene expression tended to decrease by supplementation of l-Arg with an increased level of SO compared with control. Conclusion: Supplementation with l-Arg and combination of PO and SO at the ratio of 4 : 2 could inhibit lipogenesis and subsequent lower abdominal fat deposition and enhance growth performance and carcass yield in broiler chickens. Implications: Ratio of PO and SO, 4 : 2 with l-Arg supplementation in the dietary of broiler chickens can contribute to a better growth performance, lesser fat deposition and greater carcass yield. Modern broilers have a high ability for excess fat accumulation due to genetic selections which decreases carcass yield and affects consumer acceptance of broiler meat for health-conscious issue. Supplementation with L-arginine and combination of different oil sources that rich in polyunsaturated fatty acids are effective for improving weight gain, reducing abdominal fat deposition and improve meat production in broiler chickens. [ABSTRACT FROM AUTHOR]

l-Arginine (L-Arg) depletion has attracted great attention in cancer therapy. Although two types of arginine-depleting enzymes, arginine deiminase (ADI) and human arginase I, are undergoing clinical trials, random site of PEGylation, low efficacy of heavy metal as co-factor, and immunogenicity limit the performance of these drugs and cause difficulty in a homogeneous production. Here we screened ten catalytic metal ions and have successfully produced a site-specific mono-PEGylated human arginase I mutant by conjugating the Cys45 residue to PEG-maleimide to minimize the decrease in activity and produce a homogeneous product. The catalytic efficiency trend of metal ion–enriched human arginase I mutant (HAI) was Co2+ > Ni2+ ≫ Mn2+. The overall kcat/KM values of Co-HAI and Ni-HAI were higher than Mn-HAI by ~ 8.7- and ~ 5.2-folds, respectively. Moreover, the results of enzyme kinetics and circular dichroism spectrometry demonstrated that the 20 or 40 kDa linear and branched PEG attached on the HAI surface did not affect the enzyme activity and the protein secondary structures. In vitro studies showed that both Co-HAI-PEG20L and Ni-HAI-PEG20L inhibited the growth of eight types of cancer cell lines. The pharmacodynamic study in mice demonstrated that the i.p. administration of Co-HAI-PEG20L at 13 mg/kg and Ni-HAI-PEG20L at 15 mg/kg was able to maintain a L-Arg level below its detection limit for over 120 h after one injection. The body weights of mice could return to normal levels within 5 days after injection, showing that the doses were well-tolerated. Therefore, both the Ni-HAI-PEG20L and Co-HAI-PEG20L are promising candidates for cancer therapy. Key Points: • Mono-PEGylation applied on human arginase I mutant (HAI) successfully. • The catalytic efficiency of Co- and Ni-enriched HAI was higher than the wild type. • At least eight types of cancer cell lines were inhibited by Co- and Ni-HAI-PEG20L. • Co- and Ni-HAI-PEG20L were able to achieve weekly depletion of L-Arg. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Jilin University (Science Edition) / Jilin Daxue Xuebao (Lixue Ban) is the property of Zhongguo Xue shu qi Kan (Guang Pan Ban) Dian zi Za zhi She and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Acta Prataculturae Sinica is the property of Acta Prataculturae Sinica Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

L-arginine (L-Arg) depletion induced by randomly PEGylated arginine deiminase (ADI-PEG20) can treat arginosuccinate synthase (ASS)-negative cancers, and ADI-PEG20 is undergoing phase III clinical trials. Unfortunately, ASS-positive cancers are resistant to ADI-PEG20. Moreover, the yield of ADI production is low because of the formation of inclusion bodies. Here, we report a thermostable arginine-depleting enzyme, Bacillus caldovelox arginase mutant (BCA-M: Ser161->Cys161). An abundant amount of BCA-M was easily obtained via high cell-density fermentation and heat treatment purification. Subsequently, we prepared BCA-M-PEG20, by conjugating a single 20 kDa PEG monomer onto the Cys161 residue via thio-chemistry. Unlike ADI-PEG20, BCA-M-PEG20 significantly inhibited ASS-positive lung cancer cell growth. Pharmacodynamic studies showed that a single intraperitoneal injection (i.p). administration of 250 U/mouse of BCA-M-PEG20 induced low L-Arg level over 168 h. The mono-PEGylation of BCA-M prolonged its elimination half-life from 6.4 to 91.4 h (a 14-fold increase). In an A549 lung cancer xenograft model, a weekly administration of 250 U/mouse of BCA-M-PEG20 suppressed tumor growth significantly. We also observed that BCA-M-PEG20 did not cause any significant safety issue in mouse models. Overall, BCA-M-PEG20 showed excellent results in drug production, potency, and stability. Thereby, it has great potential to become a promising candidate for lung cancer therapy. [ABSTRACT FROM AUTHOR]